Stock Market Update

[BRIEFING.COM] The major averages continue to trade in a relatively stable range, sitting mixed for the day.

Dexcom (DXCM 71.55, +4.15, +6.15%) is the top-performing S&P 500 name despite being downgraded to Underweight from Equal Weight at Barclays, with a target price of $71. The company issued upside guidance for Q4 (Dec), seeing Q4 (Dec) revs of $1.26 billion vs. the $1.24 billion FactSet Consensus. US revenue is expected to be up 11% year-over-year to approximately $892 million. International revenue is expected to be up 18% year-over-year to approximately $368 million.

The company issued in-line guidance for FY26 (Dec), seeing FY26 (Dec) revs of $5.16-5.25 billion vs. the $5.23 billion FactSet Consensus.

Meanwhile, Akamai Tech (AKAM 93.13, +5.01, +5.69%) is another top mover after being upgraded to Overweight from Underweight at Morgan Stanley, with a target price of $115.